News & Updates

Older patients with cirrhosis who are taking bisphosphonates appear to have a reduced incidence of fractures overall, according to a study.

Individuals with diets high in animal fat and protein and low in carbohydrates appear to be at heightened risk of hepatocellular carcinoma (HCC), according to a Singapore study.

Secondary prophylaxis with rifaximin monotherapy is significantly more efficacious than lactulose monotherapy in preventing the recurrence of overt HE and is well tolerated in patients with cirrhosis who are in overt HE remission, suggests a post hoc analysis of 2 randomized trials presented at EASL 2024

The investigational dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor survodutide helps reduce the histological activity of metabolic dysfunction-associated steatohepatitis (MASH) as well as improve fibrosis, according to the phase II 1404-0043 trial.

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The intelligent liver function test (iLFT) platform has made strides in a primary care system in Scotland, facilitating detection of chronic liver disease while reducing unnecessary specialist referrals, as reported in a study.